Company intelligence / Profile preview

Changchun High-Tech Industries

Ownership: Private
Development stage: Commercial

Overview

Changchun High-Tech Industries has a robust commercial portfolio with multiple approved products in China and internationally. Its pipeline includes recombinant proteins, biosimilars, and vaccines targeting chronic diseases and infectious conditions. The company is recognized for its innovation in biopharmaceuticals and strategic partnerships with global firms[3][9].

Therapeutic areas: Infectious DiseasesWomen's HealthRare DiseasesHematology
Modalities: Small moleculeMonoclonal antibodyProphylactic vaccineChemical drug
Industry: Biotech

Partnerships

Alvotech – joint venture for development/manufacture of biosimilars in China

Beyond the preview

Go deeper on Changchun High-Tech Industries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changchun High-Tech Industries.

Explore the full profile